Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Donna L. Forrest, MD, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Mary-Margaret Keating, MD FRCPC, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136162

Published: 2020

Journal Articles

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Claire Andrews, Taylor Young, Eshetu G Atenafu, M.Sc., P.Stat, Sarit E Assouline, MD MSc, Joseph M Brandwein, MD, Steven M Chan, MD PhD, Signy Chow, MD FRCP(C), Dina Khalaf, BSc, MSc, MD, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MD, Dawn Maze, MDFRCPC,MSc, Mark D. Minden, Caroline J McNamara, MBBS, Tracy Murphy, MDFRCP,FRCPath, David Sanford, MD, Aaron D Schimmer, MD PhD, Andre C. Schuh, Karen W.L. Yee, MD, Hassan Sibai, MBBS

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142990

Published: 2020

Journal Articles

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Donna L. Forrest, MD, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Mary-Margaret Keating, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-136163

Published: 2020

Journal Articles

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Peter Duggan, MD FRCPC, Donna E. Reece, MD, Kevin Song, MD, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD BSc, Martha L Louzada, MDMSc, Hira S Mian, MD, Michael Sebag, MD PhD FRCPC, Darrell J White, MD, Julie Stakiw, MD, Richard Leblanc, MD FRCPC, Esther Masih-Khan, Eshetu G Atenafu, M.Sc., P.Stat, Rami Kotb, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BS, MBA, Christopher P. Venner, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139689

Published: 2020

Journal Articles

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML): Princess Margaret Cancer Centre Experience

Muhned Alhumaid, MD, Georgina S Daher-Reyes, MD, Wilson Lam, MD, Arjun Law, MDDM, Tracy Murphy, MDFRCP,FRCPath, Caroline J McNamara, MBBS, Gil Yerushalmi, Aaron D Schimmer, MD PhD, Andre C. Schuh, MD, Dawn Maze, MDFRCPC,MSc, Eshetu G Atenafu, M.Sc., P.Stat, Karen W.L. Yee, MD, Mark D. Minden, MD PhD, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Hassan Sibai, MBBS

Blood (2019) 134 (Supplement_1): 2609.

https://doi.org/10.1182/blood-2019-125449

Published: 2019

Journal Articles

Pilot Study on Frailty and Functionality on Routine Clinical Assessment in Allogeneichematopoietic Cell Transplantation to Predict Outcomes

Maria Queralt Salas, MD, Eshetu G Atenafu, M.Sc., P.Stat, Ora Bascom, Allo-HSCT Coordinator, Leeann Wilson, RN, BSc, BSc N(HON), CON(c), Arjun Law, MDDM, Wilson Lam, MD, David Loach, MD, Zeyad Al-Shaibani, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MDDM, Jonas Mattsson, MD, Alibhai M.H. Shabbir, MD, Rajat Kumar, MD

Blood (2019) 134 (Supplement_1): 380.

https://doi.org/10.1182/blood-2019-126071

Published: 2019

Journal Articles

Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?

Sahar Khan, Eshetu G Atenafu, M.Sc., P.Stat, Christine I Chen, MD, Esther Masih-Khan, PhD, Lavinia Aileen Jeyanathan, Anca Prica, MD, Donna E Reece, MD, Rodger E Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Vishal Kukreti, MD

Blood (2019) 134 (Supplement_1): 5704.

https://doi.org/10.1182/blood-2019-130733

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia

Blood (2019) 134 (Supplement_1): 5725.

https://doi.org/10.1182/blood-2019-129078

Published: 2019

Journal Articles

Combination of ATG and Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Peripheral Blood Stem Cell Transplants for High-Risk Hematological Malignancies- a Single Centre Experience

Shruti Prem Sudha, MD DM, Eshetu G Atenafu, M.Sc., P.Stat, Queralt Salas Gay, MD, Zoe Evans, Zeyad Al-Shaibani, MD, David Loach, MD, Arjun Law, MDDM, Wilson Lam, MD, Santhosh Thyagu, MD DM, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Auro Viswabandya, MD DM

Blood (2018) 132 (Supplement 1): 4569.

https://doi.org/10.1182/blood-2018-99-111955

Published: 2018

Journal Articles

Molecular Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphologic Relapse in the Majority of Patients with Core-Binding Factor AML

Robert Puckrin, MD, Eshetu G Atenafu, M.Sc., P.Stat, Jaime Claudio, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Dawn Maze, MDFRCPC,MSc, Caroline J McNamara, MBBS, Mark D. Minden, MD PhD, Andre Schuh, Tracy Murphy, MDFRCP,FRCPath, Hassan Sibai, MBBS, Karen W.L. Yee, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Aaron D Schimmer, MD PhD

Blood (2018) 132 (Supplement 1): 436.

https://doi.org/10.1182/blood-2018-99-113090

Published: 2018

Journal Articles

Infectious Complications in the Outpatient and Inpatient Autologous Stem Cell Transplantation Setting for Patients with Multiple Myeloma. Princess Margaret Cancer Center Experience

Anna Nikonova, MD, Christina Zeglinski, NP, Shahid Husain, MD MS, Miranda So, PharmD, Eshetu G Atenafu, M.Sc., P.Stat, Donna E Reece, MD, Suzanne Trudel, MD FRCP(C), Vishal Kukreti, MD, Rodger E. Tiedemann, Anca Prica, MD, Norman Anthony Franke, MD, Jane Huynh, NP, Leeping Tao, NP, Christine I Chen, MD

Blood (2018) 132 (Supplement 1): 4614.

https://doi.org/10.1182/blood-2018-99-118775

Published: 2018

Journal Articles

Real World Outcomes of Newly Diagnosed High-Risk Multiple Myeloma Patients Treated at Princess Margaret Cancer Centre: A Retrospective Chart Review

Donna Reece, BA, MD, John Mikhaeil, Esther Masih-Khan, PhD, Eshetu G Atenafu, M.Sc., P.Stat, Christine I Chen, MD FRCP(C), Vishal Kukreti, MD FRCP(C), Anca Prica, MD FRCP(C), Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 2010.

https://doi.org/10.1182/blood.V130.Suppl_1.2010.2010

Published: 2017

Journal Articles

Toxicity and Outcomes of Autologous Stem Cell Transplant in Multiple Myeloma Patients with Renal Insufficiency: An Institutional Comparison between Two Eras

Amanda Li, MD BSc, Eshetu G Atenafu, M.Sc., P.Stat, Rosanne St. Bernard, MD MSc, Esther Masih-Khan, PhD, Donna Reece, MD FRCP(C), Norman Anthony Franke, MD, Rodger Tiedemann, MBChB, PhD, Anca Prica, MD FRCP(C), Suzanne Trudel, MD FRCP(C), Vishal Kukreti, MD FRCP(C), Christine I Chen, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 4537.

https://doi.org/10.1182/blood.V130.Suppl_1.4537.4537

Published: 2017

Journal Articles

Does Venous Thromboembolism Prophylaxis Policy Have Any Impact on Clot Risk Reduction in Hospitalized Solid Tumor Patients at Princess Margaret Cancer Centre: A Longitudinal Study?

Anna Xu, Tian Wang, Eshetu G Atenafu, M.Sc., P.Stat, Hassan Sibai, MBBS, Arjun Datt Law, MBBS, MD DM, Kelsey Japs, Joseph Samuel, andreW. Stessman, Triyu Vather, Helen Vu, Jack Seki, PharmD, Jennifer Carter

Blood (2017) 130 (Supplement 1): 5651.

https://doi.org/10.1182/blood.V130.Suppl_1.5651.5651

Published: 2017

Journal Articles

Preliminary Results of FDG-PET Scanning after GDP Chemotherapy Prior to Autologous Stem Cell Transplant (ASCT) for Relapsed/Refractory (RR) Lymphoma

Matthew D. Cooper, Umberto Falcone, MD PhD, Naom Tau, MD, Eshetu G Atenafu, M.Sc., P.Stat., Richard Tsang, MD, David C. Hodgson, MD, Armand Keating, MD, Ur Metser, MD, Michael Crump, MD, John G. Kuruvilla, MD

Blood (2016) 128 (22): 4645.

https://doi.org/10.1182/blood.V128.22.4645.4645

Published: 2016

Journal Articles

Addition of Cyclophosphamide, on Demand, to Lenalidomide and Corticosteroids in Patients with Relapsed/Refractory Multiple Myeloma, a Retrospective Review of a Single Centre Experience

Majed Alahmadi, MBBS, FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, M.Sc., P.Stat., Limore Arones, Christine Chen, MD, Vishal Kukreti, MD, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Anca Prica, MD, Donna Reece

Blood (2015) 126 (23): 1842.

https://doi.org/10.1182/blood.V126.23.1842.1842

Published: 2015

Journal Articles

Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience

Bethany E Monteith, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, M.Sc., P.Stat., Christine Chen, MD, Anca Prica, MD, Donna Reece, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Vishal Kukreti, MD

Blood (2015) 126 (23): 5361.

https://doi.org/10.1182/blood.V126.23.5361.5361

Published: 2015

Journal Articles

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., P.Stat., Andre C Schuh, MD FRCPC, Mark D. Minden, MD PhD, Aaron D. Schimmer, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Mohamed Shanavas, MD FRACP, FRCPA, Andrzej Lutynski, MD, Amr Rostom, MD, Anna Rydlewski, MD, Dina Khalaf, BSc, MSc, MD, Karen W.L. Yee, MD

Blood (2015) 126 (23): 4893.

https://doi.org/10.1182/blood.V126.23.4893.4893

Published: 2015

Journal Articles

Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., P.Stat., Joseph Brandwein, MD FRCPC, Vikas Gupta, MD FRCP, FRCPath, Johann Hitzler, MD FRCP (C), FAAP, Dina Khalaf, BSc, MSc, MD, Andrzej Lutynski, MD, Aaron D. Schimmer, MD PhD, Andre C Schuh, MD FRCPC, Amr Rostom, MD, Anna Rydlewski, MD, Karen W.L. Yee, MD, Mark D. Minden, MD PhD

Blood (2015) 126 (23): 3717.

https://doi.org/10.1182/blood.V126.23.3717.3717

Published: 2015

NARROW

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML): Princess Margaret Cancer Centre Experience

Pilot Study on Frailty and Functionality on Routine Clinical Assessment in Allogeneichematopoietic Cell Transplantation to Predict Outcomes

Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?

Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia

Combination of ATG and Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Peripheral Blood Stem Cell Transplants for High-Risk Hematological Malignancies- a Single Centre Experience

Molecular Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphologic Relapse in the Majority of Patients with Core-Binding Factor AML

Infectious Complications in the Outpatient and Inpatient Autologous Stem Cell Transplantation Setting for Patients with Multiple Myeloma. Princess Margaret Cancer Center Experience

Real World Outcomes of Newly Diagnosed High-Risk Multiple Myeloma Patients Treated at Princess Margaret Cancer Centre: A Retrospective Chart Review

Toxicity and Outcomes of Autologous Stem Cell Transplant in Multiple Myeloma Patients with Renal Insufficiency: An Institutional Comparison between Two Eras

Does Venous Thromboembolism Prophylaxis Policy Have Any Impact on Clot Risk Reduction in Hospitalized Solid Tumor Patients at Princess Margaret Cancer Centre: A Longitudinal Study?

Preliminary Results of FDG-PET Scanning after GDP Chemotherapy Prior to Autologous Stem Cell Transplant (ASCT) for Relapsed/Refractory (RR) Lymphoma

Addition of Cyclophosphamide, on Demand, to Lenalidomide and Corticosteroids in Patients with Relapsed/Refractory Multiple Myeloma, a Retrospective Review of a Single Centre Experience

Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only